RCE advances Phase 3, expands MENA licensing, secures non-dilutive funding
RCE advanced two pivotal Phase 3 trials for diabetic foot infections, expanded licensing into MENA, and secured significant non-dilutive funding. Operating loss narrowed to $14.96M, supported by R&D tax incentives and cash for ongoing milestones.